A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01228045
Recruitment Status : Active, not recruiting
First Posted : October 25, 2010
Last Update Posted : June 22, 2016
National Cancer Centre, Singapore
Information provided by (Responsible Party):
National University Hospital, Singapore